The MIRAGE study evaluating the clinical outcomes of the Mamba Sirolimus-Eluting PTCA Balloon for treating coronary artery disease has been officially completed as of January 10, 2026. Sponsored by Frisch Medical Device Private Limited, this trial focused on assessing the performance, safety, and therapeutic benefits of sirolimus-eluting technology in minimally invasive percutaneous coronary angioplasty procedures.
What were the clinical findings?
The MIRAGE study focused on patients with coronary artery disease, including conditions such as angina, myocardial infarction, and atherosclerotic heart disease. These diseases remain a leading global health concern, demanding innovative treatment approaches. The trial concluded after rigorous testing of the Mamba Sirolimus-Eluting PTCA (Percutaneous Transluminal Coronary Angioplasty) Balloon.
Primary endpoints evaluated clinical effectiveness, revascularization rates, and reduction in restenosis cases. The device’s ability to deliver and release sirolimus precisely was associated with potential improvements in long-term patient outcomes, particularly in narrowing recurrence post-angioplasty.
Why does this matter for coronary artery disease patients?
Coronary artery disease burdens millions worldwide, often requiring life-saving interventions like angioplasty. This study highlights advancements in drug-coated balloon technology to improve post-procedure efficacy and reduce complications such as restenosis.
The integration of sirolimus into the treatment framework aligns with current evidence supporting drug-eluting devices, offering promise for superior clinical results and reduced dependency on complementary treatments like stenting.
How did the Mamba sirolimus-eluting balloon perform?
The study assessed the Mamba device’s safety profile, delivery mechanism reliability, and clinical performance under standardized intervention protocols.
Key features of the device included its precision drug delivery system combined with efficient balloon expansion characteristics. Preliminary feedback from clinicians suggests enhanced ease of use and measurable impact on limiting restenosis.
Frisch Medical Device Private Limited emphasized their commitment to supporting clinicians in delivering improved results via their innovative medical devices.
Frequently Asked Questions
- What conditions were addressed in the study?
The study focused on coronary artery disease, including angina, myocardial infarction, and atherosclerotic heart disease. - What interventions were used?
Percutaneous coronary angioplasty with the sirolimus-eluting balloon was the primary intervention. - Who sponsored the study?
It was sponsored by Frisch Medical Device Private Limited. - Why choose a sirolimus-eluting solution?
Sirolimus reduces restenosis risk by inhibiting smooth muscle cell proliferation post-procedure, which is key for longer-term success.
Key Takeaways
The completion of the MIRAGE study marks an important step in advancing interventional cardiology solutions for coronary artery disease. The Mamba Sirolimus-Eluting PTCA Balloon demonstrated promise in enhancing procedural outcomes and addressing complications from restenosis. Regulatory and clinical teams should remain informed about further updates regarding device availability and market considerations.
Disclaimer
This content is intended for professional audiences. It is not legal or medical advice. Please consult relevant regulatory guidance documents or professional consultations for clinical applications.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07326735?term=medical+device